Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01556009 · ClinicalTrials.gov registry record · Phase 2
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas
A Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome, sponsored by UCSF Benioff Children's Hospital Oakland.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT01556009: Completed Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome, sponsored by UCSF Benioff Children's Hospital Oakland.
NCT01556009 is a Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome that has completed, run by UCSF Benioff Children's Hospital Oakland. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01556009, a Phase 2 study of Basal Cell Nevus Syndrome and Gorlin's Syndrome, has completed, sponsored by UCSF Benioff Children's Hospital Oakland.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate and compare the safety and efficacy of intermittent vismodegib and of Photodynamic Therapy (PDT).
Primary Outcome
Primary: i. To compare the efficacy of (i) intermittent vismodegib vs. (ii) the efficacy of photodynamic therapy (PDT) in preventing the return of the burden of surgically eligible BCCs (SEBs) to baseline level following 7 months of continuous vismodegib therapy. ii. To compare the cumulative diameter (burden) of SEBs in patients treated intermittently with vismodegib vs. with photodynamic therapy (PDT).
Conditions Studied
Interventions
- DRUG Vismodegib
- DRUG Aminolevulinic acid %20 topical solution
Study Locations (3)
California
- Children's Hospital Oakland Research Institiute - Oakland
- Children's Hospital Research Center Oakland - Oakland
New York
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT01556009 record still lists
NCT01556009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Basal Cell Nevus Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Vismodegib is the first listed.
NCT01556009 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT01556009 about?
NCT01556009 is a clinical study titled "Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas". The purpose of this study is to evaluate and compare the safety and efficacy of intermittent vismodegib and of Photodynamic Therapy (PDT).
What is the current status of trial NCT01556009?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2012-04. Estimated completion is 2015-12.
What conditions does trial NCT01556009 study?
This clinical trial studies the following conditions: Basal Cell Nevus Syndrome, Gorlin's Syndrome.
What interventions are being tested in trial NCT01556009?
The interventions under investigation include: Vismodegib (DRUG), Aminolevulinic acid %20 topical solution (DRUG).
Who is sponsoring clinical trial NCT01556009?
This trial is sponsored by UCSF Benioff Children's Hospital Oakland, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01556009 being conducted?
This trial has 3 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01556009's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia